|
California AIDSRides
A Financial Overview of the
Ride 1994 - 2001
Figures obtained
from:
Pallotta TeamWorks'
Record of Impact 2000 from the official Pallotta TeamWorks corporate site.
Pallotta TeamWorks' Final Accounting Vs Budget Reports for CAR8 (see
footnote)
sourced from
the Los Angeles Gay & Lesbian Center and San Francisco AIDS Foundation
Legal Briefs.
Los Angeles
Report
(425K)
San Francisco
Report (505K)
The CARE Exchange strongly
suggests that people interested in participating in or donating to charity events review
the
revised
Standards
for Charitable Accountability. This includes the guideline for
charities to spend at least 65% of revenue on program expenses and no more
than 35% on fundraising and its administration. BBB Wise Giving
Alliance .
It offers guidance to donors on making informed giving decisions.
For detailed information about the California AIDS Ride visit the
Pallotta TeamWorks California AIDS Ride site
|
|
Year |
Pledge Revenue |
Other Revenue |
Total Revenue |
Total Expenses |
Return To Charities |
PTW
"Donor Dollar %"
** |
True Return to Charities
‡ |
Riders |
Cost per Rider |
Ave. Pledge Raised per
Rider |
Pledge Min. |
|
1994 |
1,386,000 |
154,000 |
1,540,000 |
527,000 |
1,013,000 |
73.1% |
65.8% |
478 |
$1,103 |
$2,900 |
$2,000 |
|
1995 |
4,916,149 |
432,851 |
5,349,000 |
2,100,000 |
3,249,000 |
66.1% |
60.7% |
1,859 |
$1,130 |
$2,645 |
$2,200 |
|
1996 |
7,495,751 |
433,249 |
7,929,000 |
3,177,000 |
4,752,000 |
63.4% |
59.9% |
2,183 |
$1,455 |
$3,434 |
$2,500 |
|
1997 |
8,977,969 |
465,031 |
9,443,000 |
3,505,000 |
5,938,000 |
66.1% |
62.9% |
2,485 |
$1,410 |
$3,613 |
$2,500 |
|
1998 |
9,342,677 |
489,323 |
9,832,000 |
3,778,000 |
6,054,000 |
64.8% |
61.6% |
2,612 |
$1,446 |
$3,577 |
$2,500 |
|
1999 |
10,949,702 |
657,298 |
11,607,000 |
3,932,000 |
7,675,000 |
70.1% |
66.1% |
2,965 |
$1,326 |
$3,693 |
$2,500 |
|
2000 |
10,632,977 |
662,023 |
11,295,000 |
4,307,000 |
6,988,000 |
65.7% |
61.9% |
2,664 |
$1,617 |
$3,991 |
$2,500 |
|
2001 |
11,046,668 |
633,332 |
11,680,000 |
5,630,000 |
6,050,000 |
54.8% |
51.8% |
2,812 |
$2,002 |
$3,928 |
$2,700 |
** PTW "Donor
Dollar Return"
This figure is determined by using 100% of "Other Revenue" to offset Total
Expenses. This tells us how much of each donor's dollar ended back
with the charities, rather than the percentage of total revenue raised
going back to the charities. This figure will not provide an
accurate indication of the exact % of all money raised to cover expenses.
|
100% less |
(Total Expenses -
Other Revenue) x 100 |
| |
Pledge Revenue |
|
‡
True Percentage Return to Charities
This is the more traditionally accepted percentage figure
organizations provide to explain return to charity against fundraising and administration costs
of the event. The figure is calculated as:
|
(Total Revenue - Total
Expenses) x 100 |
|
Total Revenue
|
|
|
|
Cumulative Results
for the event to date: 1994 - 2001
|
Total Pledges: |
$64,747,892 |
|
Total Other Revenue
(including registration fees): |
$3,927,108 |
|
Total Revenue: |
$68,675,000 |
|
Total Expenses: |
$26,956,000 |
|
Total Return to
Charities: |
$41,719,000 |
|
PTW "Donor Dollar
Return" to Charities: |
64.4%
|
|
True Return to
Charities: |
60.8% |
|
Percentage to cover
expenses: |
39.2% |
|
Total Number of Riders: |
18,058 |
|
Cost per Rider: |
$1,493 |
|
Average Pledge raised
per Rider: |
$3,586
|
Charts |
|

|
|
 |
|
 |
|
|
|
Footnote:
At the time this information was compiled Pallotta TeamWorks had yet to
publish it's 2001 Record of Impact. This was eventually released in
March 2002. As the figures are not significantly different we have
have not altered this report.
Further
reading:
Download the
Pallotta TeamWorks 2001 Record of Impact
(1.2 M, large file)
The CARE Exchange's Overview of Pallotta
TeamWorks AIDSRide & AIDS Vaccine Ride Financial Results 1994-2001
The CARE Exchange's Financial Overview of the
Boston New York / NorthEast AIDSRide 1995
- 2001
The CARE Exchange's Financial
Overview of AIDS/LifeCycle 2002
and
our News and press releases
about California AIDS Ride and other charity events
|
|
Back
to top
|
|